OXB.L - Oxford BioMedica PLC

LSE - LSE Delayed Price. Currency in GBp
15.00
+0.04 (+0.27%)
At close: 4:37PM BST
Stock chart is not supported by your current browser
Previous Close14.96
Open15.00
Bid13.50 x 2513500
Ask0.00 x 11600000
Day's Range14.92 - 15.10
52 Week Range4.91 - 15.50
Volume5,859,900
Avg. Volume7,384,443
Market Cap492.602M
Beta-0.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Have Investors Already Priced In Healthcare Growth For Oxford BioMedica PLC (LON:OXB)?
    Simply Wall St.3 months ago

    Have Investors Already Priced In Healthcare Growth For Oxford BioMedica PLC (LON:OXB)?

    Oxford BioMedica PLC (LSE:OXB), a UK£369.37M small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need forRead More...

  • Reuters3 months ago

    Oxford BioMedica wins second $100 million gene therapy contract

    Britain's Oxford BioMedica has won a second $100 million (£71.2 million) contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion. Oxford Bio said on Thursday it would receive $5 million upfront and would be eligible for various milestone payments, potentially worth in excess of $100 million, plus royalties on sales of haemophilia therapies that Bioverativ is developing. The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA into cells, for Novartis's pioneering leukaemia treatment Kymriah.

  • Reuters3 months ago

    Oxford BioMedica wins second $100 mln gene therapy contract

    Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion. Oxford Bio said on Thursday it would receive $5 million upfront and would be eligible for various milestone payments, potentially worth in excess of $100 million, plus royalties on sales of haemophilia therapies that Bioverativ is developing. The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA into cells, for Novartis's pioneering leukaemia treatment Kymriah.

  • Who Owns Oxford BioMedica PLC (LON:OXB)?
    Simply Wall St.4 months ago

    Who Owns Oxford BioMedica PLC (LON:OXB)?

    Today, I will be analyzing Oxford BioMedica PLC’s (LSE:OXB) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...

  • Oxford BioMedica PLC (LON:OXB): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.5 months ago

    Oxford BioMedica PLC (LON:OXB): Has Recent Earnings Growth Beaten Long-Term Trend?

    Today I will take a look at Oxford BioMedica PLC’s (LSE:OXB) most recent earnings update (30 June 2017) and compare these latest figures against its performance over the past fewRead More...

  • Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.6 months ago

    Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?

    Oxford BioMedica PLC (LSE:OXB) is a small-cap stock with a market capitalization of GBP £273.38M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • Reuters11 months ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.